Last reviewed · How we verify

NCT05701410: CASS-I

Prevalence of Cardiac Amyloidosis Among Patients With a History of Lumbar Spinal Stenosis.

Status unknown NA Last updated 27 January 2023
What this trial tests

NA trial testing DPD scintigraphy in Cardiac Amyloidosis in 200 participants. Status unknown.

Timeline
1 January 2023
Primary endpoint
1 February 2024
1 April 2024

Quick facts

Lead sponsorSteen Hvitfeldt Poulsen
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment200
Start date1 January 2023
Primary completion1 February 2024
Estimated completion1 April 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Steen Hvitfeldt Poulsen — full company profile →

Who can join

60 and older, any sex, with Cardiac Amyloidosis or Spinal Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study investigates the prevalence of cardiac amyloidosis among patients with a history of lumbar spinal stenosis within the last ten years in the region of central Denmark.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of DPD scintigraphy

Trials testing the same drug.

Other recruiting trials for Cardiac Amyloidosis

Currently open trials in the same condition.

Other Steen Hvitfeldt Poulsen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05701410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing